AZ-4217: A High Potency BACE Inhibitor Displaying Acute Central Efficacy in Different In Vivo Models and Reduced Amyloid Deposition in Tg2576 Mice
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Aβ, the product of APP (amyloid precursor protein), has been implicated in the pathophysiology of Alzheimer's disease (AD). β-Site APP cleaving enzyme1 (BACE1) is the enzyme initiating the processing of the APP to Aβ peptides. Small molecule BACE1 inhibitors are expected to decrease Aβ-peptide generation and thereby reduce amyloid plaque formation in the brain, a neuropathological hallmark of AD. BACE1 inhibition thus addresses a key mechanism in AD and its potential as a therapeutic target is currently being addressed in clinical studies. Here, we report the discovery and the pharmacokinetic and pharmacodynamic properties of BACE1 inhibitor AZ-4217, a high potency compound (IC50 160 pM in human SH-SY5Y cells) with an excellent in vivo efficacy. Central efficacy of BACE1 inhibition was observed after a single dose in C57BL/6 mice, guinea pigs, and in an APP transgenic mouse model of cerebral amyloidosis (Tg2576). Furthermore, we demonstrate that in a 1 month treatment paradigm BACE1 inhibition of Aβ production does lower amyloid deposition in 12-month-old Tg2576 mice. These results strongly support BACE1 inhibition as concretely impacting amyloid deposition and therefore potentially an important approach for therapeutic intervention in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 1×
“Accumulation of A in brain with age in Tg2576 mice and in AD patients is more likely to be the results of decreased transport and/or clearance of A (Hartz et al., 2010; Mawuenyega et al., 2010).”
BackgroundCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053 · cited 2×
“One such model is the Tg2576 mouse model overexpressing human APP with the Swedish mutation (APPSWE), which develops amyloid plaques at 8 –12 months of age (Hsiao et al., 1996; Kawarabayashi et al., 2001).”
BackgroundRoberds, S. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1317 · Cited by 705 · cited 1×
“BACE1 knock-out mice confirmed the pivotal role of BACE1 in A production by showing that production of A in brain was reduced (Roberds et al., 2001).”
BackgroundControl of Peripheral Nerve Myelination by the ß-Secretase BACE1
Willem, M., Garratt, A. N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., Saftig, P., Birchmeier, C., & Haass, C. (2006) · Science · doi:10.1126/science.1132341 · Cited by 703 · cited 1×
“Reports on BACE1 knock-out mice suggest that BACE1 is important during development and complete inhibition of BACE1 may result in side effects (Willem et al., 2006; Cai et al., 2012).”
BackgroundBace1 modulates myelination in the central and peripheral nervous system
Hu, X., Hicks, C. W., He, W., Wong, P., Macklin, W. B., Trapp, B. D., & Yan, R. (2006) · Nature Neuroscience · doi:10.1038/nn1797 · Cited by 608 · cited 2×
“) may be important, at least during development (Hu et al., 2006; Kim et al., 2011; Cai et al., 2012; Cao et al., 2012).”
BackgroundVassar, R., Kovacs, D. M., Yan, R., & Wong, P. C. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3657-09.2009 · Cited by 577
McConlogue, L., Buttini, M., Anderson, J. P., Brigham, E. F., Chen, K. S., Freedman, S. B., Games, D., Johnson-Wood, K., Lee, M., Zeller, M., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611687200 · Cited by 300 · cited 1×
“The role of BACE1 in A plaque deposition is further supported by a study in which transgenic mice overexpressing human mutated APP crossed onto homozygous or heterozygous BACE1 knock-out mice display reduced A generation and plaque pathology (McConlogue et al., 2007).”
Background
Cited by
Yadav, D. B., Maloney, J. A., Wildsmith, K. R., Fuji, R. N., Meilandt, W. J., Solanoy, H., Lu, Y., Peng, K., Wilson, B., Chan, P., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14021 · Cited by 49
Bace1-dependent amyloid processing regulates hypothalamic leptin sensitivity in obese mice
Meakin, P. J., Jalicy, S. M., Montagut, G., Allsop, D. J. P., Cavellini, D. L., Irvine, S. W., McGinley, C., Liddell, M. K., McNeilly, A. D., Parmionova, K., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-18388-6 · Cited by 36
Venzi, M., Tóth, M., Häggkvist, J., Bogstedt, A., Rachalski, A., Mattsson, A., Frumento, P., & Farde, L. (2017) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-170006 · Cited by 18
“Soluble brain A 40 and A 42 levels were quantified using a commercial sandwich ELISA (KMB3481 and KMB3441; Invitrogen), following a diethylamine extraction procedure described previously [36].”
Method
Metadata
- Authors
- Eketjall, S., Janson, J., Jeppsson, F., Svanhagen, A., Kolmodin, K., Gustavsson, S., Radesater, A.-C., Eliason, K., Briem, S., Appelkvist, P., Niva, C., Berg, A.-L., Karlstrom, S., Swahn, B.-M., & Falting, J.
- Venue
- Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2013-06-12
- Volume
- 33
- Issue
- 24
- Pages
- 10075-10084
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2019461415
- Cited by
- 39
- References
- 12
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AZ-4217: A High Potency BACE Inhibitor Displaying Acute Central Efficacy in Different In Vivo Models and Reduced Amyloid Deposition in Tg2576 Mice. https://app.cochat.ai/papers/10.1523/jneurosci.1165-13.2013
- The paper
- Eketjall, S., Janson, J., Jeppsson, F., Svanhagen, A., Kolmodin, K., Gustavsson, S., Radesater, A.-C., Eliason, K., Briem, S., Appelkvist, P., Niva, C., Berg, A.-L., Karlstrom, S., Swahn, B.-M., & Falting, J. (2013). AZ-4217: A High Potency BACE Inhibitor Displaying Acute Central Efficacy in Different In Vivo Models and Reduced Amyloid Deposition in Tg2576 Mice. Journal of Neuroscience. https://doi.org/10.1523/jneurosci.1165-13.2013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.